CATALYST PHARMACEUTICALS INC (CPRX) Forecast, Price Target & Analyst Ratings
NASDAQ:CPRX • US14888U1016
24.32 USD
-0.37 (-1.5%)
At close: Mar 5, 2026
24.15 USD
-0.17 (-0.7%)
After Hours: 3/5/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CATALYST PHARMACEUTICALS INC (CPRX).
Forecast Snapshot
Consensus Price Target
$35.19
+ 44.70% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.45
Revenue Estimate148.7M
ChartMill Buy Consensus
88.57%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$35.19
Upside
+ 44.70%
From current price of $24.32 to mean target of $35.19, Based on 14 analyst forecasts
Low
$32.32
Median
$34.68
High
$42.00
Price Target Revisions
1 Month
0.21%
3 Months
0.00%
Price Target Summary
14 analysts have analysed CPRX and the average price target is 35.19 USD. This implies a price increase of 44.7% is expected in the next year compared to the current price of 24.32.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
88.57%
CPRX was analyzed by 14 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about CPRX.
In the previous month the buy percentage consensus was at a similar level.
CPRX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-02-04 | Baird | Initiate | Outperform |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-09 | B of A Securities | Reiterate | Buy -> Buy |
| 2024-11-18 | Stephens & Co. | Initiate | Overweight |
| 2024-11-11 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-09 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-09 | Citigroup | Maintains | Buy -> Buy |
| 2024-06-06 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-27 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Citigroup | Initiate | Buy |
| 2024-03-07 | B of A Securities | Initiate | Buy |
| 2024-03-01 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-21 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.45
Revenue Estimate148.7M
Revenue Q2Q5.15%
EPS Q2Q-0.83%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.38%
EPS (1 Month)
-0.44%
EPS (3 Months)
15.86%
Next Earnings Summary
CPRX is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 0.45 USD and the consensus revenue estimate is 148.70M USD.
The next earnings revenue estimate has been revised upward by 0.38% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 398.204M 85.90% | 491.734M 23.49% | 588.989M 19.78% | 636.12M 8.00% | 698.28M 9.77% | 752.44M 7.76% | 860.64M 14.38% | 912.27M 6.00% | 913.25M 0.11% | 977.18M 7.00% | 957.28M -2.04% | |
| EBITDA YoY % growth | 119.693M 16.21% | 232.898M 94.58% | 295.651M 26.94% | 324.87M 9.88% | 395.03M 21.60% | 409.39M 3.64% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 86.812M -14.72% | 195.124M 124.77% | 257.778M 32.11% | 280.15M 8.68% | 317.3M 13.26% | 328.1M 3.40% | 392.55M 19.64% | 427.79M 8.98% | 482.15M 12.71% | 540.49M 12.10% | 525.09M -2.85% | |
| Operating Margin | 21.80% | 39.68% | 43.77% | 44.04% | 45.44% | 43.60% | 45.61% | 46.89% | 52.79% | 55.31% | 54.85% | |
| EPS YoY % growth | 0.81 9.46% | 1.31 61.73% | 1.69 29.01% | 1.93 14.31% | 2.16 11.83% | 2.07 -4.31% | 4.72 128.45% | 5.25 11.23% | 2.19 -58.25% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.45 -0.83% | 0.44 7.60% | 0.46 9.29% | 0.49 19.41% |
| Revenue Q2Q % growth | 148.7M 5.15% | 153.05M 4.43% | 160.05M 7.86% | 175.07M 14.71% |
| EBITDA Q2Q % growth | 77.437M 6.33% | 75.164M -11.80% | 75.605M -20.08% | N/A |
| EBIT Q2Q % growth | 66.569M 5.05% | 69.942M 5.50% | 73.078M 10.28% | 77.115M 24.69% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.95%
EPS Next 5 Year
25.46%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
8.45%
Revenue Next 5 Year
9.11%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
17.44%
EBIT Next 5 Year
N/A
CATALYST PHARMACEUTICALS INC / CPRX Forecast FAQ
What is the average price target for CATALYST PHARMACEUTICALS INC (CPRX) stock?
14 analysts have analysed CPRX and the average price target is 35.19 USD. This implies a price increase of 44.7% is expected in the next year compared to the current price of 24.32.
What is the next earnings date for CPRX stock?
CATALYST PHARMACEUTICALS INC (CPRX) will report earnings on 2026-05-05.
Can you provide the consensus estimates for CATALYST PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of CATALYST PHARMACEUTICALS INC (CPRX) is 0.45 USD and the consensus revenue estimate is 148.70M USD.
What is the consensus rating for CPRX stock?
The consensus rating for CATALYST PHARMACEUTICALS INC (CPRX) is 88.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.